vs

Side-by-side financial comparison of Cytosorbents Corp (CTSO) and electroCore, Inc. (ECOR). Click either name above to swap in a different company.

electroCore, Inc. is the larger business by last-quarter revenue ($9.2M vs $9.2M, roughly 1.0× Cytosorbents Corp). electroCore, Inc. runs the higher net margin — -32.8% vs -59.5%, a 26.7% gap on every dollar of revenue. On growth, electroCore, Inc. posted the faster year-over-year revenue change (31.2% vs 0.9%). Over the past eight quarters, electroCore, Inc.'s revenue compounded faster (30.3% CAGR vs 1.3%).

CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.

electroCore, Inc. is a medical technology company based in Basking Ridge, New Jersey. electroCore was co-founded in 2005 by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD. The current chief executive officer is Daniel S. Goldberger. electroCore has one product called gammaCore, a non-invasive, commercially available product that uses vagus nerve stimulation.

CTSO vs ECOR — Head-to-Head

Bigger by revenue
ECOR
ECOR
1.0× larger
ECOR
$9.2M
$9.2M
CTSO
Growing faster (revenue YoY)
ECOR
ECOR
+30.3% gap
ECOR
31.2%
0.9%
CTSO
Higher net margin
ECOR
ECOR
26.7% more per $
ECOR
-32.8%
-59.5%
CTSO
Faster 2-yr revenue CAGR
ECOR
ECOR
Annualised
ECOR
30.3%
1.3%
CTSO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTSO
CTSO
ECOR
ECOR
Revenue
$9.2M
$9.2M
Net Profit
$-5.5M
$-3.0M
Gross Margin
73.7%
88.4%
Operating Margin
-47.5%
-31.8%
Net Margin
-59.5%
-32.8%
Revenue YoY
0.9%
31.2%
Net Profit YoY
27.4%
6.0%
EPS (diluted)
$-0.09
$-0.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTSO
CTSO
ECOR
ECOR
Q4 25
$9.2M
$9.2M
Q3 25
$9.5M
$8.7M
Q2 25
$9.6M
$7.4M
Q1 25
$8.7M
$6.7M
Q4 24
$9.2M
$7.0M
Q3 24
$8.6M
$6.6M
Q2 24
$8.8M
$6.1M
Q1 24
$9.0M
$5.4M
Net Profit
CTSO
CTSO
ECOR
ECOR
Q4 25
$-5.5M
$-3.0M
Q3 25
$-3.2M
$-3.4M
Q2 25
$1.9M
$-3.7M
Q1 25
$-1.5M
$-3.9M
Q4 24
$-7.6M
$-3.2M
Q3 24
$-2.8M
$-2.5M
Q2 24
$-4.3M
$-2.7M
Q1 24
$-6.1M
$-3.5M
Gross Margin
CTSO
CTSO
ECOR
ECOR
Q4 25
73.7%
88.4%
Q3 25
70.3%
86.0%
Q2 25
70.9%
87.3%
Q1 25
71.1%
84.9%
Q4 24
68.4%
85.9%
Q3 24
61.0%
83.8%
Q2 24
73.5%
86.3%
Q1 24
76.5%
83.7%
Operating Margin
CTSO
CTSO
ECOR
ECOR
Q4 25
-47.5%
-31.8%
Q3 25
-30.2%
-33.2%
Q2 25
-37.6%
-47.5%
Q1 25
-44.5%
-56.9%
Q4 24
-37.1%
-43.6%
Q3 24
-56.1%
-40.4%
Q2 24
-40.4%
-42.2%
Q1 24
-51.8%
-70.7%
Net Margin
CTSO
CTSO
ECOR
ECOR
Q4 25
-59.5%
-32.8%
Q3 25
-33.4%
-39.2%
Q2 25
20.2%
-49.7%
Q1 25
-16.9%
-57.4%
Q4 24
-82.7%
-45.8%
Q3 24
-32.1%
-38.1%
Q2 24
-48.6%
-43.2%
Q1 24
-67.7%
-64.4%
EPS (diluted)
CTSO
CTSO
ECOR
ECOR
Q4 25
$-0.09
$-0.34
Q3 25
$-0.05
$-0.40
Q2 25
$0.03
$-0.44
Q1 25
$-0.02
$-0.47
Q4 24
$-0.14
$-0.37
Q3 24
$-0.05
$-0.31
Q2 24
$-0.08
$-0.38
Q1 24
$-0.11
$-0.53

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTSO
CTSO
ECOR
ECOR
Cash + ST InvestmentsLiquidity on hand
$6.2M
$11.6M
Total DebtLower is stronger
$7.8M
Stockholders' EquityBook value
$5.9M
$-1.7M
Total Assets
$44.2M
$18.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTSO
CTSO
ECOR
ECOR
Q4 25
$6.2M
$11.6M
Q3 25
$7.5M
$13.0M
Q2 25
$10.2M
$7.1M
Q1 25
$11.6M
$7.8M
Q4 24
$3.3M
$12.2M
Q3 24
$5.7M
$12.9M
Q2 24
$8.5M
$14.2M
Q1 24
$8.6M
$7.8M
Total Debt
CTSO
CTSO
ECOR
ECOR
Q4 25
$7.8M
Q3 25
$7.8M
Q2 25
Q1 25
Q4 24
Q3 24
$13.8M
Q2 24
$13.7M
Q1 24
$4.4M
Stockholders' Equity
CTSO
CTSO
ECOR
ECOR
Q4 25
$5.9M
$-1.7M
Q3 25
$9.0M
$-1.1M
Q2 25
$11.6M
$1.1M
Q1 25
$14.5M
$4.4M
Q4 24
$11.1M
$7.5M
Q3 24
$13.4M
$9.5M
Q2 24
$17.4M
$11.5M
Q1 24
$19.6M
$4.5M
Total Assets
CTSO
CTSO
ECOR
ECOR
Q4 25
$44.2M
$18.7M
Q3 25
$45.8M
$21.4M
Q2 25
$48.0M
$14.6M
Q1 25
$50.8M
$16.0M
Q4 24
$47.4M
$20.5M
Q3 24
$47.8M
$21.0M
Q2 24
$53.4M
$22.4M
Q1 24
$47.1M
$13.9M
Debt / Equity
CTSO
CTSO
ECOR
ECOR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
1.03×
Q2 24
0.78×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTSO
CTSO
ECOR
ECOR
Operating Cash FlowLast quarter
$-4.8M
$-1.5M
Free Cash FlowOCF − Capex
$-4.9M
FCF MarginFCF / Revenue
-53.4%
Capex IntensityCapex / Revenue
1.2%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-12.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTSO
CTSO
ECOR
ECOR
Q4 25
$-4.8M
$-1.5M
Q3 25
$-2.6M
$-1.7M
Q2 25
$-1.5M
$-623.0K
Q1 25
$-3.5M
$-4.4M
Q4 24
$-2.3M
$-1.3M
Q3 24
$-2.5M
$-1.4M
Q2 24
$-4.8M
$-1.8M
Q1 24
$-4.8M
$-2.6M
Free Cash Flow
CTSO
CTSO
ECOR
ECOR
Q4 25
$-4.9M
Q3 25
$-2.6M
$-1.7M
Q2 25
$-1.5M
$-648.0K
Q1 25
$-3.5M
$-4.4M
Q4 24
$-2.4M
Q3 24
$-2.6M
Q2 24
$-4.8M
Q1 24
$-4.9M
FCF Margin
CTSO
CTSO
ECOR
ECOR
Q4 25
-53.4%
Q3 25
-27.3%
-19.3%
Q2 25
-16.1%
-8.8%
Q1 25
-39.7%
-65.4%
Q4 24
-26.3%
Q3 24
-30.4%
Q2 24
-54.4%
Q1 24
-54.2%
Capex Intensity
CTSO
CTSO
ECOR
ECOR
Q4 25
1.2%
0.0%
Q3 25
0.2%
0.0%
Q2 25
0.4%
0.3%
Q1 25
0.0%
0.6%
Q4 24
0.8%
Q3 24
1.8%
Q2 24
0.2%
Q1 24
0.5%
Cash Conversion
CTSO
CTSO
ECOR
ECOR
Q4 25
Q3 25
Q2 25
-0.78×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTSO
CTSO

Direct$5.1M55%
Distributors And Strategic Partners$4.2M45%

ECOR
ECOR

Segment breakdown not available.

Related Comparisons